Valuation : PREDILIFE

Market Cap 4.3M 5M 4.06M 3.7M 6.91M 478M 6.97M 48.33M 18.6M 243M 18.78M 18.37M 770M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 9.08M 10.56M 8.57M 7.8M 14.59M 1.01B 14.72M 102M 39.26M 512M 39.64M 38.78M 1.63B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-5.50%
1 week-8.04%
Current month-8.04%
1 month-18.58%
3 months-61.28%
6 months-67.51%
Current year-65.78%
1 week 1.03
Extreme 1.03
1.24
1 month 1.03
Extreme 1.03
1.5
Current year 0.9
Extreme 0.9
4
1 year 0.9
Extreme 0.9
4
3 years 0.9
Extreme 0.9
24
5 years 0.9
Extreme 0.9
24
10 years 0.9
Extreme 0.9
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
27/7/23 Buy

Chief Executive Officer

1,200 0.0328%
23/3/22 Sell

Chief Executive Officer

3,000 0.0820%
9/3/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-5.50%-8.04%-68.31%-81.61% 5M
-0.98%-1.36%+95.13%+289.00% 3.9B
-2.79%-6.38%+242.23%+35.07% 3.82B
-2.20%-4.06%+39.05%+69.45% 3.53B
+1.86%+1.83%+280.87%+509.48% 2.59B
-1.38%-3.92%-30.26%-30.82% 2.11B
-5.67%+2.26%+54.60% - 1.69B
-1.94%-8.41%+159.62%-35.22% 1.04B
+3.79%-1.87%+21.62%+41.57% 1.03B
-0.10%-1.62%+6.82%+55.36% 624M
Average -1.55%-0.36%+80.14%+94.70% 2.03B
Weighted average by Cap. -1.48%-0.48%+117.12%+150.24%

Financials

2024 2025
Net sales 493K 573K 465K 424K 792K 54.83M 800K 5.54M 2.13M 27.81M 2.15M 2.11M 88.33M 836K 972K 789K 718K 1.34M 92.92M 1.36M 9.39M 3.61M 47.13M 3.65M 3.57M 150M
Net income -4.26M -4.96M -4.02M -3.67M -6.85M -474M -6.91M -47.92M -18.44M -240M -18.62M -18.21M -764M -3.93M -4.57M -3.71M -3.38M -6.32M -437M -6.38M -44.21M -17.02M -222M -17.18M -16.8M -705M
Net Debt 3.54M 4.11M 3.34M 3.04M 5.69M 393M 5.74M 39.76M 15.3M 200M 15.45M 15.11M 634M 4.78M 5.56M 4.51M 4.11M 7.68M 531M 7.75M 53.69M 20.66M 269M 20.86M 20.41M 856M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
11/09/26 EUR 1.030 -5.50% 560
09/09/26 EUR 1.090 0.00% 744
08/09/26 EUR 1.090 -12.10% 2,007
07/09/26 EUR 1.240 0.00% 100
04/09/26 EUR 1.240 +10.71% 135

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!